Figure 1.
Comparison of PFS and OS with prognostic factors of patients with MM
| PFS* | Log Rank p-value | os*,# | Log Rank p | |||
|---|---|---|---|---|---|---|
| n | 52.7 | 77# | ||||
| Gender, n | Female / Male | 73/77 | 89.3 /39.2 | 0.080 | 66# / 69# | 0.690 |
| Age, n | <65 / >65 | 130/20 | 54.3 / 40.4 | 0.230 | 56# / 54# | 0.058 |
| Stage (Durie-Salmon), n | II/III | 38/84 | 28.5 / 54.3 | 0.257 | 87.1 / 99.1 | 0.229 |
| A/B | 91/31 | 40.4 / 65.0 | 0.277 | 55# / 51# | 0.301 | |
| IPI, n | I | 39 | 69.3 | 99.1 | ||
| II | 34 | 40.4 | 70# | |||
| III | 50 | 52.7 | 0.764 | 88.2 | 0.026 | |
| ECOG, n | < 1 / >1 | 109/12 | 47.1 / 28.5 | 0.959 | 53# / 31.4 | 0.301 |
| LDH (IU/L), n | <480 / >480 | 116/7 | 52.7 / 17 | 0.086 | 53# / 17 | 0.001 |
| CRP (mg/L), n | <5 / > 5 | 51/71 | 54.3 / 52.7 | 0.686 | 85# /99.1 | 0.057 |
| PER3 | 4R/4R | 70 | 40.4 | 74# | ||
| 4R/5R | 64 | 69.3 | 57# | |||
| 5R/5R | 16 | 86# | 0.046 | 100# | 0.349 | |
| PER-3 | 4R/4R | 70 | 40.4 | 63# | ||
| 4R/5R -5R/5R | 80 | 89.6 | 0.028 | 99.1 | 0.738 |
Comparison of frequencies of PER-3 gene variants between patients with MM and healthy controls
| PER3 | Genotype | Multiple Myeloma | Healthy Controls | OR Exp(B) | 95% CI | p |
|---|---|---|---|---|---|---|
| Genotypes | n=a (%) | n=100 (%) | ||||
| PER-3 | 4R/4R | 70 (46.7) | 42 (42) | 0.657* | 0.285-1.517* | 0.325* |
| 4R/5R | 64 (43.3) | 44 (44) | 0.745* | 0.320-1.734* | 0.494* | |
| 5R/5R | 16 (10.7) | 14 (14) | 1.363& | 0.633-2.935& | 0.434& | |
| Allele | ||||||
| 4R | 204 (67.5) | 128 (64) | ||||
| 5R | 98 (32.5) | 72 (36) | 1.159& | 0.796-1.689& | 0.443& |
Clinical features and treatment regimens of MM patients
| Multiple Myeloma | Control | Control | p | |||
|---|---|---|---|---|---|---|
| median | na (%) | median | nb (%) | |||
| Age | 56 (32-70) | 53 (28-68) | 0.140* | |||
| Gender | Female/Male | 77/73 (51.3/48.7) | 55/45 (55/45) | 0.367& | ||
| MM Subtypes | κ/λ | 83/39 (68/32) | ||||
| G/A | 79/18 (65/15) | |||||
| Light chain | 25 (20) | |||||
| Stage (Durie-Salmon) | II/III | 38/84 (25/75) | ||||
| A/B | 91/31 (79/21) | |||||
| IPI | I | 39 (32) | ||||
| II/III | 34/50 (28/40) | |||||
| ECOG | >1 | 12 (10) | ||||
| Hemoglobin | gr/dL | 10.4 (6.2-15) | ||||
| Leukocyte | mm3 | 7200 (2760-18500) | ||||
| Platelet | 103μL | 172 (69-406) | ||||
| C-reactive protein | mg/dL | 8 (2.1-352) | ||||
| LDH | IU/L | 212 (93-1037) | ||||
| B2-microglobulin | mg/L | 4.9 (1.5-48) | ||||
| Albumin | gr/L | 3.5 (1.6-5.1) | ||||
| Treatment | VCD, ASCT, LD | |||||
| OS (10-years, %) | (79) | |||||
| PFS (10-years, %) | (47) – 52.7 months | |||||
| Relapse | 63 (42) | |||||
| Mortality | 23 (15.3) | |||||
| Follow-up duration, months, (range) | 36.1 (4.1-155.2) |
Multivariate analysis of 150 MM patients (Cox proportional hazard model backward)
| PFS | ||||
|---|---|---|---|---|
| Exp (B) | %95 CI | p | ||
| PER-3 | 4R/4R | 0.488 | 0.284-0.837 | 0.009 |
| LDH | ≥480 | 0.441 | 0.170-1.141 | 0.091 |
| Gender | Female/Male | 0.604 | 0.357-1.022 | 0.060 |